Track the 한미약품 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 한미약품 has logged 26 reports. Market capitalisation: €5,243.3bn. The latest transaction was disclosed on 11 August 2026 (Purchase). Among the most active insiders: 국민연금공단. The full history is accessible without an account.
25
Insider Decl.
n/a
Thresholds
n/a
23 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 한미약품 Strong Buy (bullish), based on 12 analysts. Average price target: ₩599,167.
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,401 of 29,024 companies
55.7
score / 100
Value
39
Quality
72
FCF yld1.5%
Earn yld2.6%
EV/EBITDA20.9x
ROE16%
Gross mgn57%
Net mgn11%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Hanmi Pharmaceutical is a South Korean pharmaceutical company focused on the research and development of drugs. It is listed on the Korea Exchange (XKRX).